IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v13y2022i1d10.1038_s41467-022-34079-x.html
   My bibliography  Save this article

Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution

Author

Listed:
  • Nicole M. Sodir

    (University of Cambridge
    Genentech, Department of Translational Oncology)

  • Luca Pellegrinet

    (University of Cambridge)

  • Roderik M. Kortlever

    (University of Cambridge)

  • Tania Campos

    (University of Cambridge)

  • Yong-Won Kwon

    (Abcam, 860 Auburn Ct)

  • Shinseog Kim

    (Center for Genomic Integrity, Institute for Basic Science)

  • Daniel Garcia

    (Oncogenesis Thematic Research Center at Bristol Myers Squibb)

  • Alessandra Perfetto

    (University of Cambridge)

  • Panayiotis Anastasiou

    (University of Cambridge)

  • Lamorna Brown Swigart

    (University of California)

  • Mark J. Arends

    (University of Edinburgh)

  • Trevor D. Littlewood

    (University of Cambridge)

  • Gerard I. Evan

    (University of Cambridge
    The Francis Crick Institute)

Abstract

Germ-line hypomorphism of the pleiotropic transcription factor Myc in mice, either through Myc gene haploinsufficiency or deletion of Myc enhancers, delays onset of various cancers while mice remain viable and exhibit only relatively mild pathologies. Using a genetically engineered mouse model in which Myc expression may be systemically and reversibly hypomorphed at will, we asked whether this resistance to tumour progression is also emplaced when Myc hypomorphism is acutely imposed in adult mice. Indeed, adult Myc hypomorphism profoundly blocked KRasG12D-driven lung and pancreatic cancers, arresting their evolution at the early transition from indolent pre-tumour to invasive cancer. We show that such arrest is due to the incapacity of hypomorphic levels of Myc to drive release of signals that instruct the microenvironmental remodelling necessary to support invasive cancer. The cancer protection afforded by long-term adult imposition of Myc hypomorphism is accompanied by only mild collateral side effects, principally in haematopoiesis, but even these are circumvented if Myc hypomorphism is imposed metronomically whereas potent cancer protection is retained.

Suggested Citation

  • Nicole M. Sodir & Luca Pellegrinet & Roderik M. Kortlever & Tania Campos & Yong-Won Kwon & Shinseog Kim & Daniel Garcia & Alessandra Perfetto & Panayiotis Anastasiou & Lamorna Brown Swigart & Mark J. , 2022. "Reversible Myc hypomorphism identifies a key Myc-dependency in early cancer evolution," Nature Communications, Nature, vol. 13(1), pages 1-14, December.
  • Handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34079-x
    DOI: 10.1038/s41467-022-34079-x
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-022-34079-x
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-022-34079-x?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Megan J. Bywater & Deborah L. Burkhart & Jasmin Straube & Arianna Sabò & Vera Pendino & James E. Hudson & Gregory A. Quaife-Ryan & Enzo R. Porrello & James Rae & Robert G. Parton & Theresia R. Kress &, 2020. "Reactivation of Myc transcription in the mouse heart unlocks its proliferative capacity," Nature Communications, Nature, vol. 11(1), pages 1-17, December.
    2. Andreas Trumpp & Yosef Refaeli & Thordur Oskarsson & Stephan Gasser & Mark Murphy & Gail R. Martin & J. Michael Bishop, 2001. "c-Myc regulates mammalian body size by controlling cell number but not cell size," Nature, Nature, vol. 414(6865), pages 768-773, December.
    3. Laura Soucek & Jonathan Whitfield & Carla P. Martins & Andrew J. Finch & Daniel J. Murphy & Nicole M. Sodir & Anthony N. Karnezis & Lamorna Brown Swigart & Sergio Nasi & Gerard I. Evan, 2008. "Modelling Myc inhibition as a cancer therapy," Nature, Nature, vol. 455(7213), pages 679-683, October.
    4. Susanne Walz & Francesca Lorenzin & Jennifer Morton & Katrin E. Wiese & Björn von Eyss & Steffi Herold & Lukas Rycak & Hélène Dumay-Odelot & Saadia Karim & Marek Bartkuhn & Frederik Roels & Torsten Wü, 2014. "Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles," Nature, Nature, vol. 511(7510), pages 483-487, July.
    5. Susanne Walz & Francesca Lorenzin & Jennifer Morton & Katrin E. Wiese & Björn von Eyss & Steffi Herold & Lukas Rycak & Hélène Dumay-Odelot & Saadia Karim & Marek Bartkuhn & Frederik Roels & Torsten Wü, 2014. "Correction: Corrigendum: Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles," Nature, Nature, vol. 516(7531), pages 440-440, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Joy Edwards-Hicks & Huizhong Su & Maurizio Mangolini & Kubra K. Yoneten & Jimi Wills & Giovanny Rodriguez-Blanco & Christine Young & Kevin Cho & Heather Barker & Morwenna Muir & Ania Naila Guerrieri &, 2022. "MYC sensitises cells to apoptosis by driving energetic demand," Nature Communications, Nature, vol. 13(1), pages 1-16, December.
    2. Rebecca J. Austin & Jasmin Straube & Rohit Halder & Yashaswini Janardhanan & Claudia Bruedigam & Matthew Witkowski & Leanne Cooper & Amy Porter & Matthias Braun & Fernando Souza-Fonseca-Guimaraes & Si, 2023. "Oncogenic drivers dictate immune control of acute myeloid leukemia," Nature Communications, Nature, vol. 14(1), pages 1-14, December.
    3. Yuri Frosi & Yen-Chu Lin & Jiang Shimin & Siti Radhiah Ramlan & Kelly Hew & Alf Henrik Engman & Anil Pillai & Kit Yeung & Yue Xiang Cheng & Tobias Cornvik & Par Nordlund & Megan Goh & Dilraj Lama & Za, 2022. "Engineering an autonomous VH domain to modulate intracellular pathways and to interrogate the eIF4F complex," Nature Communications, Nature, vol. 13(1), pages 1-22, December.
    4. William Senapedis & Kayleigh M. Gallagher & Elmer Figueroa & Jeremiah D. Farelli & Robert Lyng & J. Graeme Hodgson & Charles W. O’Donnell & Joseph V. Newman & Madison Pacaro & Stephen K. Siecinski & J, 2024. "Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models," Nature Communications, Nature, vol. 15(1), pages 1-17, December.
    5. Sukanya Panja & Mihai Ioan Truica & Christina Y. Yu & Vamshi Saggurthi & Michael W. Craige & Katie Whitehead & Mayra V. Tuiche & Aymen Al-Saadi & Riddhi Vyas & Shridar Ganesan & Suril Gohel & Frederic, 2024. "Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC," Nature Communications, Nature, vol. 15(1), pages 1-24, December.
    6. Laura Curti & Sara Rohban & Nicola Bianchi & Ottavio Croci & Adrian Andronache & Sara Barozzi & Michela Mattioli & Fernanda Ricci & Elena Pastori & Silvia Sberna & Simone Bellotti & Anna Accialini & R, 2024. "CDK12 controls transcription at damaged genes and prevents MYC-induced transcription-replication conflicts," Nature Communications, Nature, vol. 15(1), pages 1-18, December.
    7. Dilraj Lama & Thibault Vosselman & Cagla Sahin & Judit Liaño-Pons & Carmine P. Cerrato & Lennart Nilsson & Kaare Teilum & David P. Lane & Michael Landreh & Marie Arsenian Henriksson, 2024. "A druggable conformational switch in the c-MYC transactivation domain," Nature Communications, Nature, vol. 15(1), pages 1-14, December.
    8. Anja Deutzmann & Delaney K. Sullivan & Renumathy Dhanasekaran & Wei Li & Xinyu Chen & Ling Tong & Wadie D. Mahauad-Fernandez & John Bell & Adriane Mosley & Angela N. Koehler & Yulin Li & Dean W. Felsh, 2024. "Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma," Nature Communications, Nature, vol. 15(1), pages 1-13, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-34079-x. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.